China Vaccine Scandal: Hundreds Demoted But Root Causes Remain

In a high-profile gesture of showing no tolerance towards poor product quality and management, China has arrested over 200 and punished 357 officials, but root cause of the scandal is much harder to root out in a short term, observers say.

BEIJING – Chinese citizens have long held suspicions over the reliability of vaccines. Due to strict requirements for temperature-controlled transportation and storage, the products can easily lose their potency if these conditions are not met.

The latest vaccine quality scandal has once again put China's health regulators on high alert, after a mother and daughter team named Pang in Jinan, Shandong province was found to be distributing to many provinces for years Category 2 vaccines, despite

More from China

Hengrui Set For Biggest Biopharma IPO So Far This Year

 

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By 

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Chinese Vaccine Makers Turn To Emerging Markets

 

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Focus On Asia